Key financial metrics for Sino Biopharmaceutical (HKEX: 1177) include multi-billion-dollar annual revenues driven by robust sales in oncology, liver disease, and respiratory therapeutics. The enterprise maintains solid gross profit margins, healthy return on equity ratios, and a manageable debt structure backed by substantial cash reserves from operations and lucrative drug licensing partnerships. Analysts monitor metrics such as price-to-earnings multiples, earnings per share growth projections, and free cash flow yields during quarterly reporting cycles.